Modulim to Present at LSI Emerging MedTech Summit

Modulim’s CEO, Charlie Huiner, will be presenting at this year’s LSI 2021 Emerging Medtech Summit in Dana Point, CA May 11^th-13^th 2021. Modulim’s FDA-cleared Clarifi® Imaging solution is well positioned to help healthcare providers manage patients with diabetes, kidney disease, and peripheral arterial disease who are at risk for lower limb complications. SFDI is a reimbursable under a proprietary CPT code. It is estimated that $237B is spent the US alone on diabetes care, of which $60B is directly related to reactive lower limb care. Modulim’s technology enables proactive management of at-risk limbs with rapid microvascular assessment at the point of care.

“We are excited to share the key milestones achieved by our team the past 18 months at LSI Medtech. Modulim is at a key inflection point and we look forward to connecting with capital partners at LSI,” said Charlie Huiner, CEO of Modulim. “The right partners can support growth as our team drives towards improving the lives of millions of patients dealing with chronic disease.”

Modulim will be presenting at this year’s LSI 2021 Emerging Medtech Summit in Dana Point, CA May 11^th-13^th 2021. LSI’s mission is to provide unique market insights so companies can deliver life changing technologies, faster.